

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	C1040/7010 (HCL/MAT)	PTO
First Named Inventor or Application Identifier		S.
DAVIS, et al.		8 U
Express Mail Label No	o. EL583585920US	ຕ8ໃ <b>ກ</b> ັ
Date of Deposit	January 22, 2001	

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents	ADDRESS Box Patent Application Commissioner for Patents Washington, DC 20231				
<ol> <li>□ Fee Transmittal Form         (Submit an original, and a duplicate for fee processing)</li> <li>□ Specification [Total pages = 90]         70 - pages description         1 - pages abstract         19 - pages claims         153 - Total claims</li> <li>□ Drawing(s) (35 USC 113) [Total sheets = 14]</li> </ol>	<ul> <li>6. □ Microfiche Computer Program (Appendix)</li> <li>7. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)</li> <li>a. ☒ Computer Readable Copy</li> <li>b. ☒ Paper Copy (identical to computer copy)</li> <li>c. ☒ Statement verifying identity of above</li> </ul>				
☑ Informal ☐ Formal [Total drawings = 14]	ACCOMPANYING APPLICATION PARTS				
4. □ Oath or Declaration [Total pages]	8. ☐ Assignment Papers/cover sheet & documents(s)				
a. ☐ Newly executed (original or copy)	9. □ 37 CFR 3.73(b) Statement				
<ul> <li>b. ☐ Copy from a prior application (37 CFR 1.63(d))         (for continuation/divisional with Box 17 completed)</li></ul>	(when there is an assignee) □ Power of Attorney				
i. DELETION OF INVENTOR(S)	10. ☐ English Translation of Document (if applicable)				
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	11. ☐ Information Disclosure Statement PTO-1449 ☐ Copies of IDS Citations				
5. ☐ Incorporation by Reference	12. ☐ Preliminary Amendment				
(usable if Box 4b is checked)  The entire disclosure of the prior application, from which a copy of the oath or declaration is	13.  Return Receipt Postcard (MPEP 503) (Should be specifically itemized)				
supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	14. ☐ Small Entity Statement(s)☐ Statement filed in prior application, Status still proper and desired				
	15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)				
16. Other:					
17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:					
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:					
☐ Cancel in this application original claims of the prior application before calculating the filing fee.					
☐ Amend the specification by inserting before the first line the sentence:					

This application is a  $\square$  continuation  $\square$  divisional of application serial no. , filed , entitled , and now .

Attorney Docket No.: C1040/7010 (HCL/MAT)

18. CORRESPONDENCE ADDRESS					
Correspondence address below					
ATTORNEY'S NAME	Helen C. Lockhart, Reg. No. 39,248				
NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	МА	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441

19. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
NAME	Helen Ç, Lockhart, Reg. No. 39,248		
SIGNATURE	alle hallant		
DATE	Jonuary 20 2001		



## 01-24-01

ATTORNEY'S DOCKET NO: C1040/7010 (HCL/MAT)

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Heather L. Davis and Michael J. McCluskie

Serial No:

not yet assigned Herewith

Filed: For:

IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING A TH2

IMMUNE RESPONSE

Examiner:

Not yet assigned

Art Unit:

Not yet assigned

Express Mail No.:

EL583585920US

## CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.10(a)

I hereby certify that this document is being placed in the United States mail as Express Mail No. EL583585920US, postage attached, addressed to Box Patent Application: Commissioner for Patents, Washington, D.C. 20231 on the 22<sup>nd</sup> day of January, 2001.

Maryanne Trevisan

Commissioner for Patents Washington, D.C. 20231

**Attention: Box Patent Application** 

Sir:

TRANSMITTAL

Transmitted herewith are the following documents:

[X] Utility Patent Application Transmittal

[X] Specification (Total Pages 90)

(70 pages of Description, 1 page of Abstract, 19 pages of Claims (153 claims),

- [X] Drawings (Total Pages 14) (Figs. 1-14)
- [X] Statement Under 37 C.F.R. §1.821(f)
- [X] Paper Sequence Listing (2 pages)
- [X] 3.5" Computer Disk
- [X] Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

Respectfully Submitted,

Helen C. Lockhart (Reg. No. 39,248)

Wolf, Greenfield & Sacks, P.C.

Federal Reserve Plaza, 600 Atlantic Avenue

Boston, MA 02210-2211

(617)720-3500

Attorneys for Applicants

Attorney Docket No.: C1040/7010 (HCL/MAT)

Date: January 22, 2001

x01/22/01

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS

Heather L. Davis and Michael J. McCluskie

SERIAL NO. : EXPRESS MAIL NO.:

Not Yet Assigned EL583585920US

FILED

Herewith

FOR

IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING

A TH2 IMMUNE RESPONSE

Commissioner for Patents Washington, D.C. 20231 BOX PATENT APPLICATION

#### STATEMENT UNDER 37 C.F.R. §1.821(f)

Sir:

This statement is made pursuant to 37 CFR 1.821(f). Applicant encloses herewith an original copy of the Sequence Listing and a computer readable diskette. Applicant's agent states that the content of the paper copy of the Sequence Listing and the computer readable diskette contain the identical information and contain no new matter.

Respectfully submitted,

Helen C. Lockhart Reg. No. 39,248

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210

Tel.: 617-720-3500

DATE: January 22, 2001

Attorney's Docket No.: C1040/7010 (HCL/MAT)

x01/22/01